🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Menin inhibitors continue to show tremendous promise in AML w/ encouraging clinical activity as single agents and now in comb. w/ HMA’s + Ven in R/R AML w/ NPM1 or KMT2Ar. Great presentation by Ghayas Issa on SAVE trial. Hopeful these agents will make a huge impact in AML. #ASH23

Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML Ghayas Issa MD Anderson Cancer Center ASH #ASH23 #ASH2023 #leusm onclive.com/view/revumenib…

dWIZ from the chemical biology wiz Jay Bradner, M.D. and team Novartis. Amazing plenary!! #ASH2023

Wonderful editorial by Dr Bernt on Barajas et al showing the latest addition to the “club”. Eytan and I have been brewing this trial for a while and it’s finally about to open: menin inhibition for the HOX-high club (including UBTF-TD based on this work) classic.clinicaltrials.gov/ct2/show/NCT06…

Watch author Y. David Seo MD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24: vimeo.com/932607668/63ad… MD Anderson Cancer Center

Nice! Congrats Y. David Seo MD!! Forgive you for missing eclipse events :)

Asciminib frontline!

👉👉Delighted to present results of an investigator-initiated trial of Pirto + Ven + Obin as firstline Rx of pts with #CLL at European Hematology Association #EHA2024 A thread 🧵

Menin inhibitors seek to debut as newest targeted therapy for leukaemia bit.ly/3xsRP99 Find out how small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias in this news article

How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley Dana-Farber #HemeNeoDivision ashpublications.org/blood/article-…

Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval ascopubs.org/doi/10.1200/JC…

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute #Leukemia (AUGMENT-101): brnw.ch/21wM2Yh #leusm

We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration Ghayas Issa MD Anderson Cancer Center

The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD

Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)

"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa. U.S. FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: brnw.ch/21wOL2U Ghayas Issa #EndCancer

Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (Ghayas Issa, MD Anderson Cancer Center). cancerletter.com/trials-and-tri…